New restrictions have been imposed by the European Medicines Agency on the coadministration of the anti-HIV drug atazanavir with a variety of other agents.
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs, but the effect was not found at 24 weeks.
With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are in sight.
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings.